IceCure Medical Ltd. has announced that its ProSense® system is the first and only medical device to receive U.S. FDA marketing authorization for the local treatment of early-stage low-risk breast cancer in patients aged 70 and above, in combination with adjuvant endocrine therapy. ProSense® utilizes liquid nitrogen-based cryoablation technology as a minimally invasive alternative to surgery, targeting tumors quickly and with minimal pain. The device is approved for use in over 15 countries, including the United States, Europe, Brazil, India, and China, and has received recognition such as the 2024 Scientific Impact Award from the American Society of Breast Surgeons for its ICE3 clinical trial data. Reimbursement pathways have been established, including a CPT Category III code for facility fees related to breast cancer cryoablation. You can access the full presentation through the link below.